{"id":7261,"date":"2013-06-05T03:45:13","date_gmt":"2013-06-05T07:45:13","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=7261"},"modified":"2013-06-05T03:45:13","modified_gmt":"2013-06-05T07:45:13","slug":"vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261","title":{"rendered":"Vermillion Inc. (NASDAQ:VRML) focus on development of diagnostic tests"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/05\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Vermillion Inc. (NASDAQ:VRML) had declined by 12.97 percent to close at $3.01 per share for the end of last trading session on Tuesday. The shares of the company had been trading in the range of $2.79 to $3.50 during the day. The shares of Vermillion Inc. (NASDAQ:VRML) had recorded 52 week low price level of $1.03 per share and 52 week high price level of $4.07 per share.<\/p>\n<p style=\"text-align: justify;\">Vermillion Inc. (NASDAQ:VRML) is involved in providing improved diagnostic tests for physicians so that they could better their test results from patients and thereby design effective treatment plans. The company is primarily engaged in the design, development, marketing and commercialization of diagnostic tests for better outcomes. Vermillion Inc. (NASDAQ:VRML) focuses on developing diagnostic tests which would combine several biomarkers into a single, reportable and readable index score.<\/p>\n<p style=\"text-align: justify;\">The diagnostic tests to be developed by Vermillion Inc. (NASDAQ:VRML) would cover diseases such as diabetics, cancer, cardiology and women\u2019s health with initial focus on ovarian cancer. The company\u2019s principal product candidate, OVA1 provides for the assessment of malignant ovarian tumor in women at the pre surgical stage itself, which had thereby addressed an unmet clinical need.<\/p>\n<p style=\"text-align: justify;\">The shares of Vermillion Inc. (NASDAQ:VRML) had witnessed heavy trading volume with nearly 1.08 million shares being exchanged hands on Tuesday, while the average trading volume of the company is at 406,713 shares per day. The company presently holds 15.20 million shares outstanding in the market with 11 percent institutional ownership.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/05\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Vermillion Inc. (NASDAQ:VRML) had declined by 12.97 percent to close at $3.01 per share for the end [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":7262,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2198,2197],"stock_ticker":[],"class_list":["post-7261","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqvrml","tag-vermillion-inc-nasdaqvrml","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vermillion Inc. (NASDAQ:VRML) focus on development of diagnostic tests - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vermillion Inc. (NASDAQ:VRML) focus on development of diagnostic tests - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/05\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Vermillion Inc. (NASDAQ:VRML) had declined by 12.97 percent to close at $3.01 per share for the end [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-06-05T07:45:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/vermillion2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Steve Hackney\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Hackney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261\"},\"author\":{\"name\":\"Steve Hackney\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\"},\"headline\":\"Vermillion Inc. (NASDAQ:VRML) focus on development of diagnostic tests\",\"datePublished\":\"2013-06-05T07:45:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261\"},\"wordCount\":257,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/vermillion2.jpg\",\"keywords\":[\"NASDAQ:VRML\",\"Vermillion Inc. (NASDAQ:VRML)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261\",\"name\":\"Vermillion Inc. (NASDAQ:VRML) focus on development of diagnostic tests - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/vermillion2.jpg\",\"datePublished\":\"2013-06-05T07:45:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/vermillion2.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/vermillion2.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vermillion Inc. (NASDAQ:VRML) focus on development of diagnostic tests\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\",\"name\":\"Steve Hackney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"caption\":\"Steve Hackney\"},\"description\":\"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vermillion Inc. (NASDAQ:VRML) focus on development of diagnostic tests - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261","og_locale":"en_US","og_type":"article","og_title":"Vermillion Inc. (NASDAQ:VRML) focus on development of diagnostic tests - Wall Street PR","og_description":"Boston, MA 06\/05\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Vermillion Inc. (NASDAQ:VRML) had declined by 12.97 percent to close at $3.01 per share for the end [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-06-05T07:45:13+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/vermillion2.jpg","type":"image\/jpeg"}],"author":"Steve Hackney","twitter_misc":{"Written by":"Steve Hackney","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261"},"author":{"name":"Steve Hackney","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867"},"headline":"Vermillion Inc. (NASDAQ:VRML) focus on development of diagnostic tests","datePublished":"2013-06-05T07:45:13+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261"},"wordCount":257,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/vermillion2.jpg","keywords":["NASDAQ:VRML","Vermillion Inc. (NASDAQ:VRML)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261","url":"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261","name":"Vermillion Inc. (NASDAQ:VRML) focus on development of diagnostic tests - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/vermillion2.jpg","datePublished":"2013-06-05T07:45:13+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/vermillion2.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/vermillion2.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vermillion-inc-nasdaqvrml-focus-on-development-of-diagnostic-tests-7261#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Vermillion Inc. (NASDAQ:VRML) focus on development of diagnostic tests"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867","name":"Steve Hackney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","caption":"Steve Hackney"},"description":"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=7261"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7261\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/7262"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=7261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=7261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=7261"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=7261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}